Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone925-288-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.91 million
Profitability
Miscellaneous
Employees240
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Cerus (NASDAQ:CERS) Frequently Asked Questions
What is Cerus' stock symbol?
Cerus trades on the NASDAQ under the ticker symbol "CERS."
How were Cerus' earnings last quarter?
Cerus Co. (NASDAQ:CERS) announced its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.01. The biotechnology company had revenue of $18.20 million for the quarter, compared to analyst estimates of $17.55 million. Cerus had a negative return on equity of 85.73% and a negative net margin of 98.69%. The company's revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.10) earnings per share. View Cerus' Earnings History.
When is Cerus' next earnings date?
What guidance has Cerus issued on next quarter's earnings?
Cerus updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $72-75 million, compared to the consensus revenue estimate of $93.48 million.
What price target have analysts set for CERS?
1 analysts have issued 12-month price targets for Cerus' stock. Their forecasts range from $9.00 to $9.00. On average, they expect Cerus' share price to reach $9.00 in the next year. This suggests a possible upside of 63.3% from the stock's current price. View Analyst Price Targets for Cerus.
What is the consensus analysts' recommendation for Cerus?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.
What are Wall Street analysts saying about Cerus stock?
Here are some recent quotes from research analysts about Cerus stock:
- 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (8/20/2019)
- 2. Cantor Fitzgerald analysts commented, "We rate CERS Overweight and have a 12-month price target of $9. CERS commercializes INTERCEPT, the only FDA-approved system for pathogen- inactivated (PI) blood components. We believe 2019 will be a pivotal year for the company as it continues to penetrate the platelet transfusion market in key geographical regions (US and internationally), which we expect to drive double-digit revenue growth longer term. CERS is seeking regulatory approval in Europe and the US to use its INTERCEPT system to treat red cells, a company-estimated $5B market." (12/18/2018)
Has Cerus been receiving favorable news coverage?
News headlines about CERS stock have trended positive on Wednesday, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cerus earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Cerus.
Who are some of Cerus' key competitors?
Some companies that are related to Cerus include Nevro (NVRO), Glaukos (GKOS), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Atrion (ATRI), Silk Road Medical (SILK), Shockwave Medical (SWAV), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Axonics Modulation Technologies (AXNX), Tactile Systems Technology (TCMD), Luminex (LMNX) and Anika Therapeutics (ANIK).
What other stocks do shareholders of Cerus own?
Who are Cerus' key executives?
Cerus' management team includes the folowing people:
- Mr. William M. Greenman, Pres, CEO & Director (Age 52)
- Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
- Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
- Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
- Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)
Who are Cerus' major shareholders?
Cerus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (8.05%), BlackRock Inc. (7.83%), ARK Investment Management LLC (6.16%), Vanguard Group Inc. (4.99%), Nikko Asset Management Americas Inc. (3.66%) and Sumitomo Mitsui Trust Holdings Inc. (3.66%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Institutional Ownership Trends for Cerus.
Which major investors are selling Cerus stock?
CERS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Essex Investment Management Co. LLC, Morgan Stanley, King Luther Capital Management Corp, AQR Capital Management LLC, A.R.T. Advisors LLC, Bank of Montreal Can and BNP Paribas Arbitrage SA. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.
Which major investors are buying Cerus stock?
CERS stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., D. E. Shaw & Co. Inc., ARK Investment Management LLC, First Midwest Bank Trust Division, Nuveen Asset Management LLC, Bank of America Corp DE and Primecap Management Co. CA. Company insiders that have bought Cerus stock in the last two years include Laurence M Corash and William Mariner Greenman. View Insider Buying and Selling for Cerus.
How do I buy shares of Cerus?
Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cerus' stock price today?
One share of CERS stock can currently be purchased for approximately $5.51.
How big of a company is Cerus?
Cerus has a market capitalization of $773.16 million and generates $60.91 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.
What is Cerus' official website?
How can I contact Cerus?
Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]
MarketBeat Community Rating for Cerus (NASDAQ CERS)
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
